Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | LPAR3 | Q9UBY5 | 8/20 | 0.47 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.47 |
| ▸ | FDPS | P14324 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3899262 | 0.88 | MEN1 (0.37) | CYP3A4LPAR3LPAR2LPAR1FDPS | |
| SCHEMBL4267679 | 0.87 | CYP3A4 (0.47) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL814225 | 0.85 | CYP3A4 (0.48) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL4119345 | 0.81 | LPAR3 (0.48) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL5028839 | 0.80 | CYP3A4 (0.44) | CYP3A4LPAR3LPAR2LPAR1FDPS | |
| SCHEMBL6579016 | 0.79 | TSHR (0.40) | CYP3A4TSHRALDH1A1 | |
| SCHEMBL5028805 | 0.78 | CYP3A4 (0.41) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL8055462 | 0.77 | CYP3A4 (0.48) | CYP3A4LPAR3LPAR2LPAR1FDPS | |
| SCHEMBL28395754 | 0.76 | CYP3A4 (0.40) | CYP3A4LPAR3LPAR2LPAR1 | |
| SCHEMBL16816999 | 0.76 | CYP3A4 (0.52) | CYP3A4LPAR3LPAR2LPAR1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012037258-A1 | PROCESSES FOR PREPARING 1,2-SUBSTITUTED CYCLOPROPYL DERIVATIVES | ABBOTT LABORATORIES (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1939205-A1 | TRICYCLIC COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | FDFT1, COASY, HMGCR | CYP3A4 1692/4885LPAR3 511/4885LPAR2 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.